Retatrutide, an investigational triple agonist for GLP-1, GIP, and glucagon receptors, enhances metabolic regulation by amplifying insulin secretion, suppressing appetite, and increasing energy expenditure through cAMP-mediated signaling. Its multi-receptor approach promotes significant weight loss and improves glucose control, potentially surpassing dual agonists like Tirzepatide.